Are We Asking the Right Questions in COPD Drug Development?
As the industry looks beyond traditional measures such as lung function and exacerbations, a new question is emerging: What does meaningful therapeutic benefit truly look like for COPD patients?
At the COPD Drug Development Summit, Bruce Miller, Chief Scientific Officer at the COPD Foundation, will explore how patient-led insights can help redefine clinical trial endpoints and strengthen the real-world impact of emerging therapies. Joining Bruce on stage will be a patient advocate who will provide a firsthand perspective on the outcomes that matter most to those living with COPD.
Alongside experts from AstraZeneca, Sanofi, Merck & Co., Connect Biopharmaceuticals, and Harvard Medical School, Bruce will participate in a panel discussion examining how the industry can better capture patient-relevant outcomes while meeting evolving regulatory expectations
As patient-centric drug development gains momentum, these conversations could help shape the future of COPD innovation.
Find out more: https://ter.li/3v360opj